Skip to content
DataLookout
Menu

LILAC-TIMI 76NCT05712200

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 64 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Dec 30, 2027
    • Enrollment increased: 1900 → 2500 participants
    • Trial sites expanded: 734 → 789 locations
    • Study description expanded, about 117 words
    v64
  2. Minor Trial sites expanded: 721 → 734 locationsv63
  3. Minor Study sites: 681 to 721v62
  4. Minor Study sites: 651 to 681v61
  5. Minor Study sites: 605 to 651
    • Primary completion date: Aug 2026 to Aug 31, 2026
    • Study completion date: Oct 2026 to Oct 31, 2026
    • Collaborators expanded, about 2 words
    v60
Show 44 earlier versionsHide 44 earlier versions
  1. Minor Study sites: 599 to 605v59
  2. Minor Study sites: 578 to 599v58
  3. Minor Study sites: 565 to 578v57
  4. Minor Study sites: 553 to 565v56
  5. Minor Study sites: 545 to 553v55
  6. Minor Study sites: 531 to 545v54
  7. Minor Study sites: 516 to 531v53
  8. Minor Study sites: 480 to 516v52
  9. Minor Study sites: 473 to 480v51
  10. Minor Study sites: 468 to 473v50
  11. Minor Study sites: 460 to 468v49
  12. Minor Study sites: 451 to 460v48
  13. Minor Study sites: 446 to 451v47
  14. Minor Study sites: 438 to 446v46
  15. Minor Study sites: 435 to 438v45
  16. Minor Study sites: 427 to 435v44
  17. Minor Study sites: 420 to 427v43
  18. Minor Study sites: 416 to 420v42
  19. Minor Study sites: 411 to 416v41
  20. Minor Study sites: 407 to 411v40
  21. Minor Study sites: 400 to 407v39
  22. Notable Primary completion date: Jan 2025 to Aug 2026
    • Study sites: 394 to 400
    • Study completion date: Mar 2025 to Oct 2026
    v38
  23. Minor Study sites: 391 to 394v37
  24. Notable Eligibility criteria expanded, about 15 words
    • Study sites: 389 to 391
    v36
  25. Minor Study sites: 386 to 389v35
  26. Minor Study sites: 380 to 386v34
  27. Minor Study sites: 373 to 380v33
  28. Minor Study sites: 367 to 373v32
  29. Minor Study sites: 364 to 367v31
  30. Minor Study sites: 359 to 364v30
  31. Minor Study sites: 354 to 359v29
  32. Notable Eligibility criteria expanded, about 93 words
    • Study sites: 339 to 354
    v28
  33. Minor Study sites: 332 to 339v27
  34. Minor Study sites: 320 to 332v26
  35. Minor Study sites: 309 to 320v25
  36. Minor Study sites: 300 to 309v24
  37. Minor Study sites: 284 to 300v23
  38. Minor Study sites: 275 to 284v22
  39. Minor Study sites: 257 to 275v21
  40. Minor Study sites: 240 to 257v20
  41. Minor Study sites: 217 to 240v19
  42. Minor Study sites: 163 to 217v18
  43. Minor Study sites: 122 to 163v17
  44. Minor Study sites: 108 to 122v15
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)
Timeframe: Up to 30 months
Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding
Timeframe: Up to 30 months

Secondary (5)

Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), or acute limb ischemia
Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), or Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding event
Efficacy: Cardiovascular (CV) mortality
Efficacy: All-cause mortality
Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding

Arms and interventions

Abelacimab (MAA868)Experimental

Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.

PlaceboPlacebo comparator

Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.

Biologicals: Abelacimab

Drugs: Placebo

Sites

789 sites in 35 countries

United States 174, China 45, Brazil 43, India 37, Argentina 35, Poland 34, Japan 33, Bulgaria 31, Italy 29, United Kingdom 29, Canada 24, Romania 23, Spain 23, Mexico 17, South Korea 17, Hungary 16, Turkey (Türkiye) 15, Colombia 14, Greece 14, Israel 13, Malaysia 13, Serbia 12, Germany 11, Latvia 11, South Africa 11, Chile 10, Czechia 10, Philippines 10, Croatia 9, Slovakia 7, Peru 6, Sweden 4, Estonia 3, Finland 3, Puerto Rico 3